Features | VJDementia

Feature Articles

Our features section includes quick-to-read updates from ‘VJToday’ on the latest data, as well as presentations and slides from specialist meetings, and multi-media features that take a deeper dive into a topic. Occasionally, content is sponsored; if this is the case, it will be clearly marked and a full disclosure provided.

FDA approves at-home starting dose of subcutaneous lecanemab for the treatment of Alzheimer’s disease

On July 13, 2026, the U.S. Food and Drug Administration (FDA) approved a new starting dosage regimen of the subcutaneous…

AAN 2025 – Editor’s picks

Explore the key abstracts we’re most excited to hear about at the 77th American Academy of Neurology (AAN) Annual Meeting,…

FDA approves benzgalantamine for symptomatic relief of mild-to-moderate Alzheimer’s disease with reduced side effects

On 29th July 2024, the U.S. Food and Drug Administration approved benzgalantamine (Zunveyl) for the symptomatic treatment of mild-to-moderate Alzheimer’s…

FDA grants approval to anti-amyloid monoclonal antibody donanemab for the treatment of Alzheimer’s disease

On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved donanemab-azbt (Kisunla) for the treatment of Alzheimer’s disease…

World-Wide FINGER: the first global network dedicated to dementia prevention

According to the World Health Organization, there are nearly 10 million new cases of dementia every year1, making dementia prevention…

Phase III TRAILBLAZER-ALZ 2 trial: donanemab slows cognitive and functional decline in patients with early Alzheimer’s disease

Topline data has been released from Eli Lilly and Company showing that donanemab significantly slowed cognitive decline by 35% and…

FDA approves lecanemab for the treatment of Alzheimer’s disease

On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…

Amyloid in Alzheimer’s disease: toxic accumulation or loss of normal function?

New data published in the Journal of Alzheimer’s disease suggest that the loss of soluble Aβ42 predicts cognitive decline better…